What's new?

Added 21 days ago Drug news

Alnylam announces new and enhanced framework for value-based agreements to accelerate patient and provider access to Givlaari.

Alnylam Pharmaceuticals, Inc. announces a new and enhanced framework for value-based agreements (VBAs) designed to help patients with acute hepatic...

Added 2 hours ago Drug news

European Commission approves Evenity for severe osteoporosis.- Amgen + UCB

Amgen and UCB announced that the European Commission has granted marketing authorization for Evenity (romosozumab) for the treatment of severe...

Added 2 hours ago Drug news

Kite/Gilead submits BLA to FDA for KTE X19 to treat relapsed or refractory mantle cell lymphoma.

Kite, a Gilead Company announced that it has submitted a Biologics License Application (BLA) to the FDA for the investigational...

Added 2 hours ago Drug news

Phase III FeDeriCa study of Perjeta + Herceptin meets secondary endpoint in breast cancer.- Genentech/Roche + Halozyme Therapeutics

Halozyme Therapeutics announced that new data from the global phase III FeDeriCa study conducted by Genentech/Roche will be presented at...

Added 2 hours ago Drug news

Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal phase II HER2-positive metastatic breast cancer trial (DESTINY-Breast01).- Daiichi Sankyo + AstraZeneca

Daiichi Sankyo presented positive detailed data from the global pivotal phase II single-arm DESTINY-Breast01 trial of DS-8201 ([fam-] trastuzumab deruxtecan),...

Added 2 hours ago Drug news

Positive tucatinib HER2CLIMB trial results in locally advanced or metastatic HER2-positive breast cancer published in the NEJM Seattle Genetics

Seattle Genetics, Inc. announced positive pivotal data from the HER2CLIMB trial evaluating tucatinib in patients with HER2-positive metastatic breast cancer...